The first-line treatment landscape for metastatic pancreatic ductal adenocarcinoma (mPDAC) has evolved significantly, yet options remain limited for this challenging disease. This opening segment explores how performance status, age, frailty, molecular profiling, and patient preferences drive treatment selection.
Choosing between triplet and doublet regimens requires careful individualization based on performance status, comorbidities, and disease burden. This segment examines the clinical factors guiding selection between NALIRIFOX and FOLFIRINOX, including peripheral neuropathy risk, GI tolerability, and the role of genomic mutations in sensitizing tumors to platinum-based or DNA-damaging agents.
